title: Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis.
abstract: While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme.
authors.forename: F
authors.initials: F
authors.lastname: Conradie
authors.forename: G
authors.initials: G
authors.lastname: Meintjes
authors.forename: J
authors.initials: J
authors.lastname: Hughes
authors.forename: G
authors.initials: G
authors.lastname: Maartens
authors.forename: H
authors.initials: H
authors.lastname: Ferreira
authors.forename: S
authors.initials: S
authors.lastname: Siwendu
authors.forename: I
authors.initials: I
authors.lastname: Master
authors.forename: N
authors.initials: N
authors.lastname: Ndjeka
mesh_terms: D064687:Diarylquinolines / Q000627:therapeutic use*; D006297:Health Services Accessibility / Q000639:trends; D006801:Humans; D013019:South Africa; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D064687:Diarylquinolines; C493870:bedaquiline